Jefferies analyst Maury Raycroft downgraded Chimerix (CMRX) to Hold from Buy with a price target of $8.50, down from $10, after Jazz Pharmaceuticals (JAZZ) announced a deal to acquire the company for $8.55 per share or $935M in cash. Lead asset dordaviprone for diffuse midline glioma fits into Jazz’s small molecule-focused oncology pipeline, says the analyst, who believes the deal is “fair.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz
- Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals
- Chimerix downgraded to Neutral from Buy at H.C. Wainwright
- Chimerix downgraded to Neutral from Outperform at Wedbush
- Chimerix Merges with Jazz Pharmaceuticals in $935M Deal